TY - JOUR
T1 - High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients
AU - Wang, Jiun Ling
AU - Lai, Chung Hsu
AU - Lin, Hsi Hsun
AU - Chen, Wei Fang
AU - Shih, Yi Chun
AU - Hung, Chih Hsin
PY - 2013/11/1
Y1 - 2013/11/1
N2 - Patients with high vancomycin minimum inhibitory concentrations (MICs) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) infection are associated with treatment failure and poor outcomes. The main purpose of this study was to investigate the effect of hVISA on patient outcome, considering both the high vancomycin MIC and the existence of heteroresistant phenotypes. From January 2005 to December 2009, consecutive meticillin-resistant S. aureus (MRSA) isolates from 284 cases of MRSA bacteraemia receiving glycopeptide therapy were collected for further MIC and hVISA testing. The demographic distribution, clinical features and outcomes in bacteraemia patients with different vancomycin MICs and hVISA status in MRSA isolates were subsequently compared. Subjects were divided into three groups: low vancomycin MIC (<1.5 mg/L) with vancomycin-sensitive S. aureus (VSSA) (n = 50); high vancomycin MIC (≥1.5 mg/L) with VSSA (n = 218); and high vancomycin MIC with hVISA (n = 16). Cox regression analysis demonstrated that the high MIC with VSSA group exhibited significantly higher 30-day mortality than the low MIC with VSSA group [odds ratio (OR) = 2.349, 95% confidence interval (CI) 1.078-5.118]. The high MIC with hVISA phenotype was not associated with higher mortality but was independently associated with persistent MRSA bacteraemia (OR = 5.996, 95% CI 1.438-25.005). To summarise, although hVISA is correlated with persistent bacteraemia, higher mortality in high vancomycin MIC infections could not be explained by the existing hVISA phenotype. Facing persistent bacteraemia under glycopeptide therapy for 7 days, clinicians should consider shifting to an alternative class of antibiotics to treat hVISA infection.
AB - Patients with high vancomycin minimum inhibitory concentrations (MICs) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) infection are associated with treatment failure and poor outcomes. The main purpose of this study was to investigate the effect of hVISA on patient outcome, considering both the high vancomycin MIC and the existence of heteroresistant phenotypes. From January 2005 to December 2009, consecutive meticillin-resistant S. aureus (MRSA) isolates from 284 cases of MRSA bacteraemia receiving glycopeptide therapy were collected for further MIC and hVISA testing. The demographic distribution, clinical features and outcomes in bacteraemia patients with different vancomycin MICs and hVISA status in MRSA isolates were subsequently compared. Subjects were divided into three groups: low vancomycin MIC (<1.5 mg/L) with vancomycin-sensitive S. aureus (VSSA) (n = 50); high vancomycin MIC (≥1.5 mg/L) with VSSA (n = 218); and high vancomycin MIC with hVISA (n = 16). Cox regression analysis demonstrated that the high MIC with VSSA group exhibited significantly higher 30-day mortality than the low MIC with VSSA group [odds ratio (OR) = 2.349, 95% confidence interval (CI) 1.078-5.118]. The high MIC with hVISA phenotype was not associated with higher mortality but was independently associated with persistent MRSA bacteraemia (OR = 5.996, 95% CI 1.438-25.005). To summarise, although hVISA is correlated with persistent bacteraemia, higher mortality in high vancomycin MIC infections could not be explained by the existing hVISA phenotype. Facing persistent bacteraemia under glycopeptide therapy for 7 days, clinicians should consider shifting to an alternative class of antibiotics to treat hVISA infection.
UR - http://www.scopus.com/inward/record.url?scp=84885429920&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885429920&partnerID=8YFLogxK
U2 - 10.1016/j.ijantimicag.2013.07.010
DO - 10.1016/j.ijantimicag.2013.07.010
M3 - Article
C2 - 24041465
AN - SCOPUS:84885429920
VL - 42
SP - 390
EP - 394
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
SN - 0924-8579
IS - 5
ER -